Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder. (17th November 2015)

• Record Type: Journal Article
• Authors: Ozbaran, Burcu; Kose, Sezen; Yuzuguldu, Onur; Atar, Burcu; Aydin, Cahide
• Is Part Of: World journal of biological psychiatry. Volume 16:Number 8(2015)
• Page Start: 619
• Page End: 624
• Publication Date: 2015-11-17
• Subjects: attention deficit hyperactivity disorder -- combined therapy -- atomoxetine -- methylphenidate -- pharmacotherapy; Biological psychiatry -- Periodicals; Biological Psychiatry -- Periodicals; 616.89
• DOI: 10.3109/15622975.2015.1051109
• Languages: English
• ISSNs: 1562-2975

Abstract

Abstract : Objectıves. Pharmacological treatment of attention deficit hyperactivity disorder (ADHD) includes stimulant and non-stimulant medications. Our purpose in this study is to investigate efficacy, safety and tolerability of combined methylphenidate and atomoxetine pharmacotherapy. Methods. We included 12 patients of the 824 patients with ADHD using methylphenidate and atomoxetine combined therapy between the years 2010 and 2014. Kiddie-SADS, Turgay DSM-IV Based Child and Adolescent Behavior Disorders Screening and Rating Scale, Child Behavior Checklist, Clinic Global Impression Scale Severity and Impression (CGIS-S-I) scales were used. Results. Patients were between the ages of 7 and 17 years. Before combined pharmacotherapy the CGIS-S score mean was 5.08. Mean CGIS-S score after the combined pharmacotherapy was 3.08 ( P = 0.03; –2, 980). The most common side effects were irritability ( n = 5, 41.6%), appetite reduction ( n = 3, 25%), palpitations ( n = 2, 16.7%), headache ( n = 1, 8.3%). Conclusıons. Nine of these 12 patients showed significant improvement in their symptoms, combined therapy enhanced the effectiveness of monotherapy.